By Kate Kelland LONDON | Thu May 17, 2012 8:38pm EDT LONDON (Reuters) – An experimental cancer drug developed by Britain’s GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday. Results of Phase I trial published in The Lancet medical journal showed substantial shrinking of tumors in patients treated with the drug, dabrafenib, and showed promise against secondary melanoma tumors, or metastases, in the brain. Dabrafenib blocks the activity of a cancer-causing mutated form of a gene known as BRAF, which is found in about half of melanoma cases
By Andrew M. Seaman NEW YORK | Thu May 17, 2012 5:12pm EDT NEW YORK (Reuters Health) – Babies who are fed milk from their mothers’ breasts gain less weight over their first year compared to babies fed milk — breast or formula — from a bottle, suggests a new study. The lead author said the difference may come down to how much of a role babies play in deciding when to stop feeding, instead of mothers or fathers forcing them to finish a bottle.
